News and Trends 16 Dec 2022
Alchemab Therapeutics receives £1.7M grant to work on therapy for Huntington’s disease
Alchemab Therapeutics has been awarded a grant of £1.7 million ($2 million) from Innovate UK’s Biomedical Catalyst (BMC) 2022 funding competition to accelerate development of a first-in-class disease modifying therapy for Huntington’s disease. Working in collaboration with Medicines Discovery Catapult (MDC), Alchemab is carrying out preclinical studies to progress its panel of antibodies towards first […]